Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score

Adjuvant chemotherapy is beneficial for premenopausal women-and not postmenopausal women-with HR-positive, HER2-negative, early breast cancer with 1-3 lymph nodes and a recurrence score of 0-25, according to updated results from the phase III RxPonder study.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963289/
https://www.ncbi.nlm.nih.gov/pubmed/35348778
http://dx.doi.org/10.1093/oncolo/oyac012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963289/
https://www.ncbi.nlm.nih.gov/pubmed/35348778
http://dx.doi.org/10.1093/oncolo/oyac012

Ejemplares similares